BMC Cancer 2006, 6:66 http://www.biomedcentral.com/1471-2407/6/66 omas with recombinant expression of the HSVtk gene. Exper- imental Cell Research 2003, 284:185-195. 10. Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM: Mito- chondrial amplification of death signals determines thymi- dine kinase/ganciclovir-triggered activation of apoptosis. Cancer Research 2000, 60:3212-3217. 11. Yu L, Yamamoto N, Kadomatsu K, Muramatsu T, Matsubara S, Saki- yama S, Tagawa M: Midkine promoter can mediate transcrip- tional activation of a fused suicide gene in a broader range of human breast cancer compared with c-erbB-2 promoter. Oncology 2004, 66:143-149. 12. Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH, Woo SL: Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther- apy 2002, 9:168-175. 13. Maeda T, O-Wang J, Matsubara H, Asano T, Ochiai T, Sakiyama S, Tagawa M: A minimum c-erbB-2 promoter-mediated expres- sion of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganci- clovir. Cancer Gene Therapy 2001, 8:890-896. 14. A-Mohammadi S, Hawkins RE: Efficient transgene regulation from a single tetracycline- controlled positive feedback reg- ulatory system. Gene Therapy 1998, 5:76-84. 15. Hillman GG, Slos P, Wang Y, Wright JL, Layer A, De Meyer M, Yudelev M, Che M, Forman JD: Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adeno- carcinoma. Cancer Gene Therapy 2004, 11:61-72. 16. Gossen M, Freundlied S, Bender G, Muller G, Hillen W, Bujard H: Trandcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769. 17. Aurisicchio L, Bujard H, Hillen W, Cortese R, Ciliberto G, La Monica N, Palombo F: Regulated and prolonged expression of mIFN(α) in immunocompetent mice mediated by a helper- dpendent adenovirus vector. Gene Therapy 2001, 8:1817-1825. 18. Zabala M, Wang L, Hernandez-Alcoceba R, Hillen W, Qian C, Prieto J, Kramer MG: Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. Cancer Research 2004, 64:2799-2804. 19. Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi J, Velu T, Tenenbaum L: Tetracycline-inducible trans- gene expression mediated by a single AAV vector. Gene Ther- apy 2003, 10:84-94. 20. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, Galun E, Gazit Z, Jorgensen C, Gazit D: Gene therapy platform for bone regeneration using an exogenously regulated, AAV- 2-based gene expression system. Molecular Therapy 2004, 9:587-595. 21. Grimm D, Kleinschmidt JA: Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Human Gene Therapy 1999, 10:2445-2450. 22. Hu WX, Zeng ZJ, Luo SQ, Chen Q: Suicide gene therapy of human breast cancer in SCID mice model by the regulation of Tet-On. Chinese Medical Journal 2004, 117:434-439. 23. Zeng ZJ, Li ZB, Luo SQ, Hu WX: Retrovirus- mediated tk gene therapy of implanted human breast cancer in nude mice under the regulation of Tet-On. Cancer Gene Therapy 2006, 13:290-297. 24. McTaggart S, Al-Rubeai M: Retroviral vectors for human gene delivery. Biotechnology Advances 2002, 20:1-31. 25. Wang Y, Hu JK, Krol A, Li YP, Li CY, Yuan F: Systemic dissemina- tion of viral vectors during intratumoral injection. Molecular Cancer Therapy 2003, 2:1233-1242. 26. Berlinghoff S, Veldwijk MR, Laufs S, Maser HP, Jauch A, Wenz F, Jens Zeller W, Fruehauf S: Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene ther- apy. Lung Cancer 2004, 46:179-186. 27. Enger PO, Thorsen F, Lonning PE, Bjerkvig R, Hoover F: Adeno- associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum Gene Therapy 2002, 13:1115-1125. 28. Veldwijk MR, Fruehauf S, Schiedlmeier B, Kleinschmidt JA, Zeller WJ: Differential expression of a recombinent adenoassociated virus 2 vector in human CD34+ cells and breast cancer cells. Cancer Gene Therapy 2000, 7:597-604. 29. Fitzsimons HL, McKenzie JM, During MJ: Insulators coupled to a minimal bi-directional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain. Gene Therapy 2001, 8:1675-1681. 30. Lee KH, Piao H, Son BR, Heo DS, Kim NK, Kim ST: Herpes simplex virus thymidine kinase and granulocyte marcrophage col- ony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model. Cancer Gene Therapy 2004, 11:570-576. 31. Goto T, Nishi T, Kobayashi O, Tamura T, Dev SB, Takeshima H, Kochi M, Kuratsu J, Sakata T, Ushio Y: Combination electro-gene therapy using herpes virus thymidine kinase and interleukin- 12 expression plasmids is highly efficient against murine car- cinomas in vivo. Molecular Therapy 2004, 10:929-937. 32. Sobotkova E, Duskova M, Smahel M, Holan V, Janouskova O, Vonka V: Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells. Oncology Reports 2004, 12:877-883. 33. Nestler U, Wakimoto H, Siller-Lopez F, Aguilar LK, Chakravarti A, Muzikansky A, Stemmer-Rachamimov A, Chiocca EA, Aguilar-Cor- dova E, Hochberg FH: The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. Journal of Neuro-Oncology 2004, 67:177-188. 34. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W: Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. PNAS USA 2000, 97:7963-7968. 35. Qu Z, Thottassery JV, Van Ginkel S, Manuvakhova M, Westbrook L, Roland-Lazenby C, Hays S, Kern FG: Homogeneity and long-term stability of tetracycline-regulated gene expression with low basal activity by using the rtTA2S-M2 transactivator and insulator-flanked reporter vectors. Gene 2004, 327:61-73. 36. Xu ZL, Mizuguchi H, Mayumi T, Hayakawa T: Regulated gene expression from adenovirus vectors: a systematic compari- son of various inducible systems. Gene 2003, 309:145-151. 37. Shockett PE, Zhou S, Hong X, Schatz DG: Partial reconstitution of V(D)J rearrangement and lymphocyte development in RAG-deficient mice expressing inducible, tetracycline-regu- lated RAG transgenes. Molecular Immunology 2004, 40:813-829. 38. Freundlieb S, Schirra-Muller C, Bujard H: A tetracycline control- led activation/repression system with increased potential for gene transfer into mammalian cells. The Journal of Gene Medicine 1999, 1:4-12. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/6/66/prepub Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 8 of 8 (page number not for citation purposes)